



**J Collins**

**Contact**

J Collins

## Publications (16)

Gruber G, Gusterson B, Viale G, Goldhirsch A, Price K, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Castiglione-Gertsch M, Cole B, International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Ann Oncol* 2008; 19:1393-401.

Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Ann Oncol* 2007; 18:701-8.

Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. *Ann Oncol* 2005; 16:716-25.

Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. *BJC* 2004; 91:1893-901.

Berclaz G, Thürlimann B, Fey M, Mendiola C, Werner I, Simoncini E, Crivellari D, Gelber R, Goldhirsch A, Snyder R, Collins J, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam C, Holmberg S, Lindtner J, Erien D, International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 2004; 15:875-84.

Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Veas H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchard C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Luluhová D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Veas H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörgler M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlerin A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdun C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). *Strahlenther Onkol* 2004; 180 Suppl 1:89-108.

Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21:1205-13.

Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. *British journal of cancer* 2002; 86:1705-14.

Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2001; 19:4141-9.

Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:3925-35.

Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. *Lancet* 2000; 355:1869-74.

Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:1412-22.

Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Bonetti M, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. *The International Breast Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:584-90.

Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. *International Breast Cancer Study Group. European journal of cancer (Oxford, England : 1990)* 1998; 34:1693-700.

Pagani O, Price K, Fey M, Simoncini E, Thürlimann B, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C, Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Senn H. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. *European journal of cancer (Oxford, England : 1990)* 1998; 34:632-40.

Goldhirsch A, Price K, Pagani O, Fey M, Simoncini E, Cavalli F, Coates A, Crivellari D, Forbes J, Collins J, Lindtner J, Rudenstam C, Thürlimann B, O'Neill A, Castiglione M, Gelber R, Senn H. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1997; 8:751-6.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)